Galectin-3 Level in Ankylosing Spondylitis Patients

Recep Tayyip Erdogan University Training and Research Hospital80 enrolled

Overview

Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs. We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Ankylosing Spondylitis

Interventions

Serum galectin-3 concentration was measured.OTHER

Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Ankylosing spondylitis patients * Healthy controls Exclusion Criteria: * Hyperlipidemia * Liver diseases * Renal diseases * Hematological diseases * Familial thyroid diseases * Neoplastic diseases * Autoimmune infectious diseases * Receiving anti-inflammatory drugs.

Outcomes

Primary Outcomes

Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients

Correlation

Time frame: 5 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.